← Back to Clinical Trials
Recruiting NCT05911620

Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism

Trial Parameters

Condition Cushing Syndrome
Sponsor Central Hospital, Nancy, France
Study Type INTERVENTIONAL
Phase N/A
Enrollment 21
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-10-24
Completion 2026-02-28
Interventions
Magnetic resonance elastography (MRE)

Brief Summary

The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome. the HEPACORT study is the first exploratory study to assess the severity of liver fibrosis in patients with Cushing's syndrome or suspected of presenting by Magnetic Resonance Elastography (MRE).

Eligibility Criteria

Inclusion Criteria: * age ≥ 18 years old; * Person affiliated to a social security scheme or beneficiary of such a scheme; * Person having received complete information on the organization of the research and having signed informed consent; * Person having carried out a preliminary clinical examination adapted to the research. * Patients with Cushing's syndrome (for the Cushing's Syndrome group) * Patients with possible Cushing's syndrome (for the suspected Cushing's Syndrome group) defined as response to the dexamethasone supression test with 1 mg of Dexamethasone, with a plasma cortisol assay at 8 am between 18 and 50 µg/L carried out in the 3 months preceding ; * Patients with metabolic syndrome (for the metabolic syndrome group) Exclusion Criteria: * Person having taken corticosteroid therapy for more than 3 months during the 2 years preceding inclusion; * Person having received corticosteroid therapy of shorter duration with discontinuation less than one month before inclusion; *

Related Trials